What question did this study set out to answer?

To evaluate real-world 24-month treatment persistence with denosumab and associated changes in bone mineral density among postmenopausal women with osteoporosis.

August 7, 2018Archives of OsteoporosisOpen Access

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

View Full Paper

Ask AI

Bookmark

To evaluate real-world 24-month treatment persistence with denosumab and associated changes in bone mineral density among postmenopausal women with osteoporosis.
Conducted a single-arm prospective cohort study across real-world clinical practice settings in the USA and Canada (N=935 postmenopausal women receiving denosumab every 6 months).
Evaluated 24-month persistence (defined as receiving at least four injections with gaps no greater than 6 months plus 8 weeks), total injection counts, DXA-measured bone mineral density changes, and incidences of fractures and serious adverse events.
Overall 24-month persistence was 58%, with 50% persistence among US patients and 75% among Canadian patients.
At least four injections were received by 62% of US patients and 81% of Canadian patients during the observation period.
Persistent patients with serial DXA scans demonstrated mean bone mineral density increases of 7.8% at the lumbar spine and 2.1% at the femoral neck, while serious adverse events occurred in 122 patients (13.0%) and fractures in 54 patients (5.8%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective cohort study reports 58% 24-month persistence with denosumab in postmenopausal women with osteoporosis, indicating sustained treatment enhances bone mineral density.

Cite This Study

Silverman et al. (2018) studied this question.

synapsesocial.com/papers/6ab7288dc2e31ab8bf8fba48 https://doi.org/10.1007/s11657-018-0491-z

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study reports 58% 24-month persistence with denosumab in postmenopausal women with osteoporosis, indicating sustained treatment enhances bone mineral density.

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Key Points

Discussion

Implication

Cite This Study

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider